BNZ-gamma peptide, a potential therapeutic agent in HTLV-1 associated myelopathy

Similar Items

• Common γ-chain blocking peptide reduces in vitro immune activation markers in HTLV-1-associated myelopathy/tropical spastic paraparesis
  od: Massoud, Raya, i dr.
  Izdano: (2015)
• A multi-cytokine inhibitory peptide (BNZ 132-1) that is a potential therapeutic agent for HAMTSP and other necrotizing diseases.
  od: Nata, Toshie, i dr.
  Izdano: (2015)
• Immunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
  od: Enose-Akahata, Yoshimi, i dr.
  Izdano: (2019)
• Correlation of increased CXCL13 with intrathecal humoral immune responses to HTLV-1 in CSF of patients with HAM/TSP
  od: Enose-Akahata, Yoshimi, i dr.
  Izdano: (2014)
• Development of HTLV-1 associated myelopathy/tropical spastic paraparesis in a patient with simian T-lymphotropic virus type 1-like infection.
  od: Enose-Akahata, Yoshimi, i dr.
  Izdano: (2015)